Esperion to Participate in Three Upcoming Virtual Investor Conferences
October 27 2020 - 8:00AM
Esperion (NASDAQ: ESPR), today announced that members of Esperion
management will participate in three upcoming virtual conferences
during the month of November.
Event: |
|
Credit Suisse 29th Annual Virtual Healthcare Conference |
Date: |
|
November 9, 2020 |
Format: |
|
Fireside chat & 1:1 Investor meetings |
Time: |
|
2:00 p.m. ET |
|
|
|
Event: |
|
Stifel Virtual Healthcare Conference |
Date: |
|
November 17, 2020 |
Format: |
|
Fireside chat & 1:1 Investor meetings |
Time: |
|
8:40 a.m. ET |
|
|
|
Event: |
|
Jefferies Virtual London Healthcare Conference |
Date: |
|
November 18, 2020 |
Format: |
|
Fireside chat & 1:1 Investor meetings |
Time: |
|
9:40 a.m. ET |
A live audio webcast of the virtual conference presentations can
be accessed on the investor relations section of the Esperion
website at www.esperion.com/investors-media/events-presentations/.
Replay of the webcasts will be archived on the Company's website
for 90 days following the events.
Esperion Therapeutics
Through scientific and clinical excellence, and a deep
understanding of cholesterol biology, the experienced Lipid
Management Team at Esperion is committed to developing new LDL-C
lowering medicines that will make a substantial impact on reducing
global cardiovascular disease, the leading cause of death around
the world. For more information, please visit www.esperion.com and
follow us on Twitter at www.twitter.com/EsperionInc.
Esperion Therapeutics’ Commitment to Patients with
Hyperlipidemia
High levels of LDL-C can lead to a build-up of fat and
cholesterol in and on artery walls (known as atherosclerosis),
potentially leading to cardiovascular events, including heart
attack and stroke. In the U.S., 96 million people, or more than 37
percent of the adult population, have elevated LDL-C. There are
approximately 18 million people in the U.S. living with elevated
levels of LDL-C despite taking maximally tolerated lipid-modifying
therapy — including individuals considered statin averse — leaving
them at high risk for cardiovascular events1. In the United States,
more than 50 percent of atherosclerotic cardiovascular disease
(ASCVD) patients and heterozygous familial hypercholesterolemia
(HeFH) patients who are not able to reach their guideline
recommended LDL-C levels with statins alone need less than a 40
percent reduction to reach their LDL-C threshold goal2.
Esperion's mission as the Lipid Management Company is to deliver
oral, once-daily medicines that complement existing oral drugs to
provide the additional LDL-C lowering that these patients need.
References(1) Esperion market
research on file: research project interviewing 350 physicians.
Esperion Therapeutics, Inc. Sept-Oct 2018.(2) Data on
file: analysis of NHANES database. Esperion Therapeutics, Inc.
2018.
Investor Contact:Kaitlyn
BroscoEsperioninvestorrelations@esperion.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024